Axia Pharmaceutical Testosterone Cypionate Recall: CGMP Deviations Risk
Axia Pharmaceutical recalls testosterone cypionate and progesterone vials due to CGMP deviations. Affected lots may pose safety risks; check your product details.
Recall notice
CGMP Deviations
Contact the company
What happened, in plain English
Axia Pharmaceutical is recalling testosterone cypionate and progesterone vials that were compounded with CGMP deviations. This could affect product safety, though the exact risk isn't specified in the recall. Read more at govinfonow.com/recall/41508-axia-pharmaceutical-testosterone-cypionate-recall-cgmp-deviations-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/41508-axia-pharmaceutical-testosterone-cypionate-recall-cgmp-deviations-risk · Updated October 8, 2026 · FDA enforcement record: FDA #D-1040-2017
Cite this page
“Axia Pharmaceutical Testosterone Cypionate Recall: CGMP Deviations Risk.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/41508-axia-pharmaceutical-testosterone-cypionate-recall-cgmp-deviations-risk. Based on FDA recall #D-1040-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1040-2017%22&limit=1).
Why it’s dangerous
CGMP deviations mean the manufacturing process didn't meet safety standards. This could lead to product contamination or incorrect dosing, though the specific risk isn't detailed in the recall.
Who’s affected
People with prescriptions for this compounded hormone therapy are affected. Those using the product without a prescription are not impacted.
How to tell if you have this one
Check for vials labeled 'Testosterone Cypionate + Progesterone, 200 mg/2.5 mg/mL, 10 mL amber glass vials'. The lot number starts with 03022017+44906 and expires by August 29, 2017.
- Brand
Axia Pharmaceutical- Category
Drug
What to do — step by step
Check Product Details
Look for the lot number starting with 03022017+44906 and expiration date of August 29, 2017.
Where it went and when
Where it was distributed
Distributed in California.
FDA distribution: “There were only one customer in California” States read from FDA’s own wording; “not listed” means the notice does not name it.
States: California.
Recall timeline
FDA terminated this recall 18 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-1040-2017 (July 12, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1040-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.